US pharmaceutical major

美国制药巨头

Eli Lilly

礼来公司

on Thursday announced plans to launch its blockbuster

周四宣布了推出其大片的计划

diabetes drug

糖尿病药物

Mounjaro in

Mounjaro 在

KwikPen

快笔

, a single patient use prefilled pen designed for once weekly administration in the Indian market, offering a convenient treatment option for adults with

，一种专为印度市场设计的单患者使用预填充笔，每周一次给药，为成人提供便捷的治疗选择，适用于

type 2 diabetes

2型糖尿病

The announcement comes two days after its rival Danish drugmarker

该公告是在其竞争对手丹麦药标发布两天后发布的。

Novo Nordisk

诺和诺德

, launched its

，推出了它的

weight loss drug

减肥药

Wegovy as a once a week injection in India.

Wegovy在印度作为每周一次的注射剂。

The company said that they have received approval from the drug regulatory authority however did not comment on the launch timeline.

公司表示，他们已获得药品监管机构的批准，但未就上市时间表发表评论。

Lilly said each pen delivers four fixed doses of 0.6 mL and has been approved in six dose strengths including 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, the company said in a statement.

礼来公司在一份声明中表示，每支笔可提供四次0.6毫升的固定剂量，并已批准六种剂量强度，包括2.5毫克、5毫克、7.5毫克、10毫克、12.5毫克和15毫克。

“The approval of

“批准

Mounjaro

蒙贾罗

KwikPen marks a step forward in the care of people living with type 2 diabetes and obesity, offering a convenient way for patients to take their medication,” said Winselow Tucker, President and General Manager, Lilly India.

“KwikPen标志着在2型糖尿病和肥胖症患者护理方面向前迈进了一步，为患者提供了一种便捷的用药方式，”礼来印度公司总裁兼总经理温斯洛·塔克表示。

Live Events

现场活动

“With this approval, all six dosage options for Mounjaro (

“随着这一批准，Mounjaro的全部六种剂量选项（

tirzepatide

替西帕肽

) will soon be available in India, supporting a more personalised approach to treatment and allowing healthcare professionals to tailor care based on individual patient needs and clinical goals.”

`) 很快将在印度推出，支持更加个性化的治疗方案，并允许医疗专业人员根据患者个体需求和临床目标来调整护理。”`

Mounjaro (tirzepatide) is the first and only dual GIP (glucose- dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist, indicated as an adjunct to diet and exercise for the treatment of Type 2 diabetes and chronic weight management in adults with obesity or overweight, with one weight-related comorbidity..

Mounjaro（替尔扎帕肽）是首个也是唯一一个双重GIP（葡萄糖依赖性促胰岛素多肽）和GLP-1（胰高血糖素样肽-1）受体激动剂，作为饮食和运动的辅助手段，用于治疗2型糖尿病以及肥胖或超重且伴有一种体重相关并发症的成人的慢性体重管理。

Earlier in March the company had launched Mounjaro in 2.5 mg vial and 5 mg vial at Rs 3500 and Rs 4375 respectively.with diabetes and nearly half of these adult patients are inadequately treated with suboptimal glycemic control.

今年3月早些时候，该公司推出了2.5毫克和5毫克瓶装的Mounjaro，售价分别为3500卢比和4375卢比。糖尿病患者中，近一半的成年患者治疗不足，血糖控制不理想。

Mounjaro reduces body weight, and decreases fat mass by regulating appetite. Moreover, Mounjaro has been demonstrated to regulate lipid utilization.

Mounjaro能够减轻体重，通过调节食欲减少脂肪量。此外，已证明Mounjaro能够调节脂质的利用。

Over the past five years, the Indian market for weight loss drugs has grown over 30% CAGR to close to 550 crore, industry sources told ET.

过去五年，印度减肥药市场以超过30%的年均复合增长率增长，接近5.5亿卢比，行业消息人士告诉《经济时报》。

India has about 101 million people living with diabetes and nearly half of these in the adult patients category are being inadequately treated with suboptimal glycemic control.

印度约有 1.01 亿人患有糖尿病，其中近一半属于成年患者，他们因血糖控制不佳而未能得到充分治疗。